More than a month ahead of its scheduled PDUFA date, the FDA granted conditional approval for Spectrum Pharmaceuticals Inc.'s in-licensed peripheral T-cell lymphoma (PTCL) therapy, Beleodaq (belinostat), triggering a $25 million payment to the drug's owner, Topotarget A/S, and giving patients and doctors a new weapon against the fatal disease.